MedTrace Logo

Pembro+Chemo in Brain Mets

NCT04964960 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2025-10-31

Study results available
· View outcomes & findings →

Summary

The goal of this study is to evaluate whether providing Pembrolizumab prolongs survival and preserves quality of life while minimizing side effects for patients with NSCLC with untreated asymptomatic brain metastasis.

Conditions

Interventions

DRUG

Pembrolizumab

Pembrolizumab is an immunotherapy that can help fight certain cancers.

DRUG

Nab paclitaxel

Nab-paclitaxel is a taxane derivative that is an albumin-bound paclitaxel nanoparticle formulation that promotes microtubule assembly.

DRUG

Paclitaxel

Paclitaxel is a taxane derivative that promotes microtubule assembly by enhancing the action of tubulin dimers, stabilizing existing microtubules, and inhibiting their disassembly, interfering with the late G2 mitotic phase, and inhibiting cell replication.

DRUG

Pemetrexed

Pemetrexed is an antifolate agent that disrupts folate-dependent metabolic processes essential for cell replication.

DRUG

Carboplatin

Carboplatin is a platinum compound alkylating agent which covalently binds to DNA and interferes with the function of DNA by producing interstrand DNA cross-links.

Sponsors & Collaborators

  • John L. Villano, MD, PhD

    lead OTHER

Principal Investigators

  • John Villano, MD, PhD · University of Kentucky

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-19
Primary Completion
2023-06-19
Completion
2023-12-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04964960 on ClinicalTrials.gov